Drug intelligence / Profile preview

EB-203

Development stage: Phase 2
Lead developer: EyeBiotech
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

EB-203 is an investigational ophthalmic drug being developed as an eye drop formulation for the treatment of wet (neovascular/exudative) age-related macular degeneration (nAMD). Its mechanism of action involves targeting both vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF), acting as an angiogenesis inhibitor to reduce abnormal blood vessel growth in the retina. The drug is currently in Phase II clinical trials, with Eye Bio Korea serving as its developer.

Targets

PEDF (Pigment epithelium-derived factor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on EB-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-203.

Explore the full profile